Replies to post #125425 on Biotech Values

[Rocky3]

the Lovenox patent case is considered urgent by nobody.

That was not the position stated by MNTA management at the annual meeting. Well, there didn't seem to be urguency, but surely was disappointment that the judge set the date when he did. It would extremely unusual for a plaintiff to want a long-date trial schedule. That is what management indicated - they wanted a much sooner date.

It would be very unusual for a judge to have any idea how fast a government agency might act, unless one of the parties makes a point to state the fact, and I find it very unlikely TEVA would state (voluntarily or non-voluntarily) that it did not expect to get approval anytime soon. So, I am with others on the intrepretation that the case gives very little indication as to the timing of TEVA approval.

[iwfal]

the Lovenox patent case is considered urgent by nobody

Ok, not following - since the ASM reportage by the Rocky makes it clear that Momenta is(!) worried about the delay (due to the possibility of a bunch of other market entries being approved in the relatively near term) and didn't like the delay. Similarly one has to assume that Teva too had little say.

Thus the trial date was a decision made by only 1 person, different from the people previously assumed as the decision drivers on whom so much board weight was placed at the original announcement about the late date and who probably has only a little data we don't have and has much less industry/technical knowledge.